Learn how you can go about changing QC test methods and how this can go a long way to helping your lab achieve data integrity compliance.
List view / Grid view
17 May 2021 | By Bruker Biospin Group
In this on-demand webinar, Kathleen Farley (Senior Principal Scientist, R&D, Pfizer Inc) describes how nuclear magnetic resonance (NMR) spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used.
With roughly a fifth of the mass spectrometry market made up by pharma and biotech, growing R&D investment and technological breakthroughs in mass spectrometers will contribute to market growth.
Product hub: How can you ensure product quality if you are not in control of your manufacturing environment?
Without confidence in your environmental monitoring (EM) data and microbiological testing, you can never be completely sure that your products are free from unwanted microorganisms. Our Accugenix® microbial identification and strain typing services offer unparalleled accuracy that you can rely on.
Challenges and solutions to adopting MALDI technology for filamentous fungi ID with emphasis on sample preparation and database development.
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
Medicines and other healthcare products rely for their value, integrity and commercial longevity on a delicate balance between quality, safety and efficacy.
Mass spectrometry has numerous applications in pharmaceutical research, from initial discovery through to characterisation and quality control. In this article, Dr Ioannis Papayannopoulos details the role of mass spectrometry in pharma R&D by highlighting established and novel applications of the technique in drug discovery and development.
Unique advantages of incorporating untargeted and targeted metabolomics in drug development and clinical trials
11 December 2020 | By Metabolon
Watch our on-demand webinar as experts discuss the use and benefits of incorporating untargeted and targeted metabolomics into the drug development process.
The new general chapter (2.5.42) outlines three procedures for the analysis of N-nitrosamine impurities in active substances.
Determination of nitrosamines including gentoxic NDMA analysed by GC-MS in Valsartan using direct injection and headspace methods, below required LOD.
A simple, sensitive and selective direct method using IC coupled to a single quadrupole MS to analyse organic acids in drug solutions.